Get the latest on the Ceftriaxone shortage in 2026. Learn what's causing limited supply, how much it costs, and how to find it in stock near you.
If you've been prescribed Ceftriaxone recently, you may have run into an unexpected problem: your hospital, clinic, or pharmacy doesn't have it. Ceftriaxone — one of the most commonly used injectable antibiotics in the United States — has been affected by intermittent supply shortages that began in late 2023 and have continued into 2026.
This update covers the current state of the shortage, what's causing it, how much Ceftriaxone costs in 2026, and what you can do to get the treatment you need.
Yes. As of early 2026, certain Ceftriaxone formulations remain in limited supply. The shortage has particularly affected:
The situation is not a complete nationwide outage. Powder-for-injection vials (1 g and 500 mg) are more widely available, and supply has gradually improved in some regions. However, many facilities still report difficulty sourcing all the formulations they need.
The FDA and ASHP (American Society of Health-System Pharmacists) continue to track the shortage. Multiple generic manufacturers — including Sandoz, Hikma, Apotex, Fresenius Kabi, WG Critical Care, and Baxter — are working to increase production.
Several factors have combined to create and sustain this shortage:
Ceftriaxone is a sterile injectable product that must be manufactured under strict FDA-regulated conditions. Production disruptions at any single plant — whether from equipment failures, quality control issues, or facility upgrades — can significantly reduce national supply. Because only a handful of companies make generic Ceftriaxone, each manufacturer's output matters enormously.
The active pharmaceutical ingredients (APIs) for Ceftriaxone are primarily produced in India and China. Global supply chain disruptions — including regulatory actions at overseas manufacturing plants, shipping delays, and geopolitical tensions — have affected the steady flow of raw materials to U.S. manufacturers.
Ceftriaxone demand has risen as clinical guidelines increasingly recommend it as a first-line treatment for community-acquired pneumonia, gonorrhea, and other common infections. Emergency departments, in particular, use enormous volumes of this antibiotic.
The number of companies manufacturing generic sterile injectables has decreased over the past decade due to mergers, acquisitions, and plant closures. Fewer manufacturers means less production capacity and less resilience when problems arise.
For more background on why this medication is hard to find, see: Why Is Ceftriaxone So Hard to Find?
Ceftriaxone is available only as a generic (the brand name Rocephin has been discontinued), which generally keeps costs lower. However, pricing varies widely depending on formulation and where you get it:
If you're paying out of pocket, see our detailed guide on How to Save Money on Ceftriaxone in 2026.
While no new brand-name version of Ceftriaxone has launched, there are some developments that may help patients:
If your doctor needs to consider switching your treatment, we've covered the options: Alternatives to Ceftriaxone If You Can't Fill Your Prescription.
If you need Ceftriaxone now, here's what to do:
For a complete walkthrough, read: How to Find Ceftriaxone in Stock Near You.
The Ceftriaxone shortage is frustrating, but it's not hopeless. Supply is gradually improving, and there are effective alternatives available for most infections that Ceftriaxone treats. The most important thing you can do is stay in close contact with your healthcare provider and use tools like Medfinder to track availability in your area.
We'll continue to update this page as the shortage situation evolves. Bookmark it and check back for the latest information.
Related Ceftriaxone resources:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
